Expression of podoplanin in thymoma: its correlation with tumor invasion, nodal metastasis, and poor clinical outcome
Summary Recent studies have shown that podoplanin overexpression is associated with lymph node metastasis and poor clinical outcome in several malignant tumors. To investigate the role of podoplanin in thymoma, we examined 111 thymomas by immunohistochemistry using monoclonal antibody D2-40, which r...
Gespeichert in:
| Veröffentlicht in: | Human pathology 2011-04, Vol.42 (4), p.533-540 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 540 |
|---|---|
| container_issue | 4 |
| container_start_page | 533 |
| container_title | Human pathology |
| container_volume | 42 |
| creator | Tateyama, Hisashi, MD Sugiura, Hiroshi, MD Yamatani, Chihiro, MD Yano, Motoki, MD |
| description | Summary Recent studies have shown that podoplanin overexpression is associated with lymph node metastasis and poor clinical outcome in several malignant tumors. To investigate the role of podoplanin in thymoma, we examined 111 thymomas by immunohistochemistry using monoclonal antibody D2-40, which recognizes podoplanin. The tumors consisted of 8 type A, 40 type AB, 15 type B1, 23 type B2, 15 type B3, and 10 combined thymomas according to the World Health Organization histological classification system and of 41 stage I, 28 stage II, 16 stage III, 20 stage IVa, and 6 stage IVb thymomas according to the Masaoka staging system. We have found podoplanin expression in 0 (0%) type A, 4 (10%) type AB, 4 (27%) type B1, 16 (70%) type B2, 10 (67%) type B3, and 7 (70%) combined thymomas and in 5 (12%) cases of stage I, 7 (25%) of stage II, 11 (69%) of stage III, 12 (60%) of stage IVa, and all (100%) of stage IVb thymomas. Podoplanin was significantly expressed in B2/B3/combined thymomas and advanced stage thymomas ( P < .0001). On survival analysis, podoplanin expression was significantly associated with an increased risk of death for the whole group of thymomas ( P = .0002), although it was not identified as an independent prognostic factor in multivariate analysis. The significant survival curve differences of podoplanin expression were also seen for stage III/IVa/IVb thymomas ( P = .0409) and B2/B3/combined thymomas ( P = .0478). In conclusion, D2-40 immunostaining seems to be valuable for predicting the aggressive and metastatic potential of thymomas and the prognosis of the patients. |
| doi_str_mv | 10.1016/j.humpath.2010.08.012 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_858282194</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0046817710003357</els_id><sourcerecordid>858282194</sourcerecordid><originalsourceid>FETCH-LOGICAL-c477t-672b3f9b07ff980125d9bc5ba2c0891e1d65966c0a0f72f2cc2439d87de731373</originalsourceid><addsrcrecordid>eNqFkt-L1DAQx4Mo3nr6JygFEV-u6yRpmsQHRY7zBxz4oD6HNEnZrG1Tk_R0_3tTds-DexEGApnPfJmZ7yD0HMMWA27f7Le7ZZx13m0JlD8QW8DkAdpgRkktqCQP0QagaWuBOT9DT1LaA2DMGvYYnRFMKG-k2KDl6s8cXUo-TFXoqznYMA968lNVIu8OYxj128rnVJkQoxt0XsnfPu-qvIwhFuxGr9UX1RSsHqrRZZ1K-HRR6ckWxQKZwU_elGxYsgmje4oe9XpI7tnpPUc_Pl59v_xcX3_99OXyw3VtGs5z3XLS0V52wPteijIfs7IzrNPEgJDYYdsy2bYGNPSc9MQY0lBpBbeOU0w5PUevj7pzDL8Wl7IafTJuKBO6sCQlmCCCYNkU8uU9ch-WOJXmFAbaCAmCkUKxI2ViSCm6Xs3RjzoeCqRWW9RenWxRqy0KhCptl7oXJ_WlG539V3XrQwFenQCdyp76qCfj0x3XQNsCh8K9P3KubO3Gu6iS8W4yzvroTFY2-P-28u6ewq05P93BpbupVSIK1Lf1htYTwgBAKeP0L-Dmw44</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1034890852</pqid></control><display><type>article</type><title>Expression of podoplanin in thymoma: its correlation with tumor invasion, nodal metastasis, and poor clinical outcome</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Tateyama, Hisashi, MD ; Sugiura, Hiroshi, MD ; Yamatani, Chihiro, MD ; Yano, Motoki, MD</creator><creatorcontrib>Tateyama, Hisashi, MD ; Sugiura, Hiroshi, MD ; Yamatani, Chihiro, MD ; Yano, Motoki, MD</creatorcontrib><description>Summary Recent studies have shown that podoplanin overexpression is associated with lymph node metastasis and poor clinical outcome in several malignant tumors. To investigate the role of podoplanin in thymoma, we examined 111 thymomas by immunohistochemistry using monoclonal antibody D2-40, which recognizes podoplanin. The tumors consisted of 8 type A, 40 type AB, 15 type B1, 23 type B2, 15 type B3, and 10 combined thymomas according to the World Health Organization histological classification system and of 41 stage I, 28 stage II, 16 stage III, 20 stage IVa, and 6 stage IVb thymomas according to the Masaoka staging system. We have found podoplanin expression in 0 (0%) type A, 4 (10%) type AB, 4 (27%) type B1, 16 (70%) type B2, 10 (67%) type B3, and 7 (70%) combined thymomas and in 5 (12%) cases of stage I, 7 (25%) of stage II, 11 (69%) of stage III, 12 (60%) of stage IVa, and all (100%) of stage IVb thymomas. Podoplanin was significantly expressed in B2/B3/combined thymomas and advanced stage thymomas ( P < .0001). On survival analysis, podoplanin expression was significantly associated with an increased risk of death for the whole group of thymomas ( P = .0002), although it was not identified as an independent prognostic factor in multivariate analysis. The significant survival curve differences of podoplanin expression were also seen for stage III/IVa/IVb thymomas ( P = .0409) and B2/B3/combined thymomas ( P = .0478). In conclusion, D2-40 immunostaining seems to be valuable for predicting the aggressive and metastatic potential of thymomas and the prognosis of the patients.</description><identifier>ISSN: 0046-8177</identifier><identifier>EISSN: 1532-8392</identifier><identifier>DOI: 10.1016/j.humpath.2010.08.012</identifier><identifier>PMID: 21237498</identifier><identifier>CODEN: HPCQA4</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal ; Antibodies, Monoclonal, Murine-Derived ; Autoimmune diseases ; Behavior ; Biological and medical sciences ; Biomarkers, Tumor - analysis ; Biomarkers, Tumor - metabolism ; Cancer ; Classification ; Clinical outcomes ; D2-40 ; Endothelium ; Female ; Hematologic and hematopoietic diseases ; Hospitals ; Humans ; Hypotheses ; Immunohistochemistry ; Invasions ; Investigative techniques, diagnostic techniques (general aspects) ; Kaplan-Meier Estimate ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Lymph node metastasis ; Lymphatic Metastasis ; Male ; Medical sciences ; Membrane Glycoproteins - biosynthesis ; Middle Aged ; Multivariate analysis ; Neoplasm Invasiveness ; Neoplasm Staging ; Pathology ; Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques ; Pneumology ; Podoplanin ; Prognosis ; Proportional Hazards Models ; Stem cells ; Studies ; Survival analysis ; Thoracic surgery ; Thymoma ; Thymoma - metabolism ; Thymoma - mortality ; Thymoma - pathology ; Thymus Neoplasms - metabolism ; Thymus Neoplasms - mortality ; Thymus Neoplasms - pathology ; Treatment Outcome ; Tumors ; Tumors of the respiratory system and mediastinum ; Young Adult</subject><ispartof>Human pathology, 2011-04, Vol.42 (4), p.533-540</ispartof><rights>Elsevier Inc.</rights><rights>2011 Elsevier Inc.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2011 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c477t-672b3f9b07ff980125d9bc5ba2c0891e1d65966c0a0f72f2cc2439d87de731373</citedby><cites>FETCH-LOGICAL-c477t-672b3f9b07ff980125d9bc5ba2c0891e1d65966c0a0f72f2cc2439d87de731373</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0046817710003357$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24066070$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21237498$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tateyama, Hisashi, MD</creatorcontrib><creatorcontrib>Sugiura, Hiroshi, MD</creatorcontrib><creatorcontrib>Yamatani, Chihiro, MD</creatorcontrib><creatorcontrib>Yano, Motoki, MD</creatorcontrib><title>Expression of podoplanin in thymoma: its correlation with tumor invasion, nodal metastasis, and poor clinical outcome</title><title>Human pathology</title><addtitle>Hum Pathol</addtitle><description>Summary Recent studies have shown that podoplanin overexpression is associated with lymph node metastasis and poor clinical outcome in several malignant tumors. To investigate the role of podoplanin in thymoma, we examined 111 thymomas by immunohistochemistry using monoclonal antibody D2-40, which recognizes podoplanin. The tumors consisted of 8 type A, 40 type AB, 15 type B1, 23 type B2, 15 type B3, and 10 combined thymomas according to the World Health Organization histological classification system and of 41 stage I, 28 stage II, 16 stage III, 20 stage IVa, and 6 stage IVb thymomas according to the Masaoka staging system. We have found podoplanin expression in 0 (0%) type A, 4 (10%) type AB, 4 (27%) type B1, 16 (70%) type B2, 10 (67%) type B3, and 7 (70%) combined thymomas and in 5 (12%) cases of stage I, 7 (25%) of stage II, 11 (69%) of stage III, 12 (60%) of stage IVa, and all (100%) of stage IVb thymomas. Podoplanin was significantly expressed in B2/B3/combined thymomas and advanced stage thymomas ( P < .0001). On survival analysis, podoplanin expression was significantly associated with an increased risk of death for the whole group of thymomas ( P = .0002), although it was not identified as an independent prognostic factor in multivariate analysis. The significant survival curve differences of podoplanin expression were also seen for stage III/IVa/IVb thymomas ( P = .0409) and B2/B3/combined thymomas ( P = .0478). In conclusion, D2-40 immunostaining seems to be valuable for predicting the aggressive and metastatic potential of thymomas and the prognosis of the patients.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibodies, Monoclonal</subject><subject>Antibodies, Monoclonal, Murine-Derived</subject><subject>Autoimmune diseases</subject><subject>Behavior</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Cancer</subject><subject>Classification</subject><subject>Clinical outcomes</subject><subject>D2-40</subject><subject>Endothelium</subject><subject>Female</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Hypotheses</subject><subject>Immunohistochemistry</subject><subject>Invasions</subject><subject>Investigative techniques, diagnostic techniques (general aspects)</subject><subject>Kaplan-Meier Estimate</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Lymph node metastasis</subject><subject>Lymphatic Metastasis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Membrane Glycoproteins - biosynthesis</subject><subject>Middle Aged</subject><subject>Multivariate analysis</subject><subject>Neoplasm Invasiveness</subject><subject>Neoplasm Staging</subject><subject>Pathology</subject><subject>Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques</subject><subject>Pneumology</subject><subject>Podoplanin</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Stem cells</subject><subject>Studies</subject><subject>Survival analysis</subject><subject>Thoracic surgery</subject><subject>Thymoma</subject><subject>Thymoma - metabolism</subject><subject>Thymoma - mortality</subject><subject>Thymoma - pathology</subject><subject>Thymus Neoplasms - metabolism</subject><subject>Thymus Neoplasms - mortality</subject><subject>Thymus Neoplasms - pathology</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><subject>Tumors of the respiratory system and mediastinum</subject><subject>Young Adult</subject><issn>0046-8177</issn><issn>1532-8392</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkt-L1DAQx4Mo3nr6JygFEV-u6yRpmsQHRY7zBxz4oD6HNEnZrG1Tk_R0_3tTds-DexEGApnPfJmZ7yD0HMMWA27f7Le7ZZx13m0JlD8QW8DkAdpgRkktqCQP0QagaWuBOT9DT1LaA2DMGvYYnRFMKG-k2KDl6s8cXUo-TFXoqznYMA968lNVIu8OYxj128rnVJkQoxt0XsnfPu-qvIwhFuxGr9UX1RSsHqrRZZ1K-HRR6ckWxQKZwU_elGxYsgmje4oe9XpI7tnpPUc_Pl59v_xcX3_99OXyw3VtGs5z3XLS0V52wPteijIfs7IzrNPEgJDYYdsy2bYGNPSc9MQY0lBpBbeOU0w5PUevj7pzDL8Wl7IafTJuKBO6sCQlmCCCYNkU8uU9ch-WOJXmFAbaCAmCkUKxI2ViSCm6Xs3RjzoeCqRWW9RenWxRqy0KhCptl7oXJ_WlG539V3XrQwFenQCdyp76qCfj0x3XQNsCh8K9P3KubO3Gu6iS8W4yzvroTFY2-P-28u6ewq05P93BpbupVSIK1Lf1htYTwgBAKeP0L-Dmw44</recordid><startdate>20110401</startdate><enddate>20110401</enddate><creator>Tateyama, Hisashi, MD</creator><creator>Sugiura, Hiroshi, MD</creator><creator>Yamatani, Chihiro, MD</creator><creator>Yano, Motoki, MD</creator><general>Elsevier Inc</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>20110401</creationdate><title>Expression of podoplanin in thymoma: its correlation with tumor invasion, nodal metastasis, and poor clinical outcome</title><author>Tateyama, Hisashi, MD ; Sugiura, Hiroshi, MD ; Yamatani, Chihiro, MD ; Yano, Motoki, MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c477t-672b3f9b07ff980125d9bc5ba2c0891e1d65966c0a0f72f2cc2439d87de731373</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibodies, Monoclonal</topic><topic>Antibodies, Monoclonal, Murine-Derived</topic><topic>Autoimmune diseases</topic><topic>Behavior</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Cancer</topic><topic>Classification</topic><topic>Clinical outcomes</topic><topic>D2-40</topic><topic>Endothelium</topic><topic>Female</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Hypotheses</topic><topic>Immunohistochemistry</topic><topic>Invasions</topic><topic>Investigative techniques, diagnostic techniques (general aspects)</topic><topic>Kaplan-Meier Estimate</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Lymph node metastasis</topic><topic>Lymphatic Metastasis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Membrane Glycoproteins - biosynthesis</topic><topic>Middle Aged</topic><topic>Multivariate analysis</topic><topic>Neoplasm Invasiveness</topic><topic>Neoplasm Staging</topic><topic>Pathology</topic><topic>Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques</topic><topic>Pneumology</topic><topic>Podoplanin</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Stem cells</topic><topic>Studies</topic><topic>Survival analysis</topic><topic>Thoracic surgery</topic><topic>Thymoma</topic><topic>Thymoma - metabolism</topic><topic>Thymoma - mortality</topic><topic>Thymoma - pathology</topic><topic>Thymus Neoplasms - metabolism</topic><topic>Thymus Neoplasms - mortality</topic><topic>Thymus Neoplasms - pathology</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><topic>Tumors of the respiratory system and mediastinum</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tateyama, Hisashi, MD</creatorcontrib><creatorcontrib>Sugiura, Hiroshi, MD</creatorcontrib><creatorcontrib>Yamatani, Chihiro, MD</creatorcontrib><creatorcontrib>Yano, Motoki, MD</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Human pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tateyama, Hisashi, MD</au><au>Sugiura, Hiroshi, MD</au><au>Yamatani, Chihiro, MD</au><au>Yano, Motoki, MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Expression of podoplanin in thymoma: its correlation with tumor invasion, nodal metastasis, and poor clinical outcome</atitle><jtitle>Human pathology</jtitle><addtitle>Hum Pathol</addtitle><date>2011-04-01</date><risdate>2011</risdate><volume>42</volume><issue>4</issue><spage>533</spage><epage>540</epage><pages>533-540</pages><issn>0046-8177</issn><eissn>1532-8392</eissn><coden>HPCQA4</coden><abstract>Summary Recent studies have shown that podoplanin overexpression is associated with lymph node metastasis and poor clinical outcome in several malignant tumors. To investigate the role of podoplanin in thymoma, we examined 111 thymomas by immunohistochemistry using monoclonal antibody D2-40, which recognizes podoplanin. The tumors consisted of 8 type A, 40 type AB, 15 type B1, 23 type B2, 15 type B3, and 10 combined thymomas according to the World Health Organization histological classification system and of 41 stage I, 28 stage II, 16 stage III, 20 stage IVa, and 6 stage IVb thymomas according to the Masaoka staging system. We have found podoplanin expression in 0 (0%) type A, 4 (10%) type AB, 4 (27%) type B1, 16 (70%) type B2, 10 (67%) type B3, and 7 (70%) combined thymomas and in 5 (12%) cases of stage I, 7 (25%) of stage II, 11 (69%) of stage III, 12 (60%) of stage IVa, and all (100%) of stage IVb thymomas. Podoplanin was significantly expressed in B2/B3/combined thymomas and advanced stage thymomas ( P < .0001). On survival analysis, podoplanin expression was significantly associated with an increased risk of death for the whole group of thymomas ( P = .0002), although it was not identified as an independent prognostic factor in multivariate analysis. The significant survival curve differences of podoplanin expression were also seen for stage III/IVa/IVb thymomas ( P = .0409) and B2/B3/combined thymomas ( P = .0478). In conclusion, D2-40 immunostaining seems to be valuable for predicting the aggressive and metastatic potential of thymomas and the prognosis of the patients.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>21237498</pmid><doi>10.1016/j.humpath.2010.08.012</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0046-8177 |
| ispartof | Human pathology, 2011-04, Vol.42 (4), p.533-540 |
| issn | 0046-8177 1532-8392 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_858282194 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Aged Aged, 80 and over Antibodies, Monoclonal Antibodies, Monoclonal, Murine-Derived Autoimmune diseases Behavior Biological and medical sciences Biomarkers, Tumor - analysis Biomarkers, Tumor - metabolism Cancer Classification Clinical outcomes D2-40 Endothelium Female Hematologic and hematopoietic diseases Hospitals Humans Hypotheses Immunohistochemistry Invasions Investigative techniques, diagnostic techniques (general aspects) Kaplan-Meier Estimate Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Lymph node metastasis Lymphatic Metastasis Male Medical sciences Membrane Glycoproteins - biosynthesis Middle Aged Multivariate analysis Neoplasm Invasiveness Neoplasm Staging Pathology Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques Pneumology Podoplanin Prognosis Proportional Hazards Models Stem cells Studies Survival analysis Thoracic surgery Thymoma Thymoma - metabolism Thymoma - mortality Thymoma - pathology Thymus Neoplasms - metabolism Thymus Neoplasms - mortality Thymus Neoplasms - pathology Treatment Outcome Tumors Tumors of the respiratory system and mediastinum Young Adult |
| title | Expression of podoplanin in thymoma: its correlation with tumor invasion, nodal metastasis, and poor clinical outcome |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T12%3A13%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Expression%20of%20podoplanin%20in%20thymoma:%20its%20correlation%20with%20tumor%20invasion,%20nodal%20metastasis,%20and%20poor%20clinical%20outcome&rft.jtitle=Human%20pathology&rft.au=Tateyama,%20Hisashi,%20MD&rft.date=2011-04-01&rft.volume=42&rft.issue=4&rft.spage=533&rft.epage=540&rft.pages=533-540&rft.issn=0046-8177&rft.eissn=1532-8392&rft.coden=HPCQA4&rft_id=info:doi/10.1016/j.humpath.2010.08.012&rft_dat=%3Cproquest_cross%3E858282194%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1034890852&rft_id=info:pmid/21237498&rft_els_id=1_s2_0_S0046817710003357&rfr_iscdi=true |